Halozyme Therapeutics, Inc.

HALO Healthcare Biotechnology

Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 44.1%, free cash flow grew 141.2% and total debt rose 42.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

121.84 0.33 +0.27%
Market cap
$13.8B
P/E
34.6×
Fwd P/E
10.6×
Dividend yield
—
F-score
5/9
Altman Z
3.46
Beneish M
−2.59
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
173.67% 99.40% 153.59% 124.50%

+8 more TTM periods

Piotroski F-Score
5 5 5 8
ROA
17.86% 14.33% 13.81% 27.45%
ROIC
18.13% 15.64% 14.31% 35.11%
Return on Tangible Assets
61.47% 48.31% 43.39% 105.78%
Average Days of Receivables
100.00 110.82 115.33 101.62
Free Cash Flow per Share
6.87 5.65 5.38 6.31
Free Cash Flow
806.22 667.65 644.59 739.68
Capital Expenditures
(12.37) (9.76) (6.97) 128.68
Other line items
Cash ROIC
31.98% 24.89% 27.61% 27.23%
Accounts Receivable Turnover
4.31 3.96 3.73 3.93
Accounts Payable Turnover
13.83 15.19 14.69 13.84
Inventory Turnover
1.84 1.62 1.44 1.21
Average Days of Payables
29.47 19.82 33.34 29.19
Days of Inventory on Hand
171.17 218.58 281.56 353.10
Tax Rate
(0.29) (0.31) (0.32) (0.20)
Research and Development Expense of Revenue
23.28% 25.00% 26.23% 5.63%
Selling, General and Administrative Expense of Revenue
14.30% 14.76% 14.83% 13.86%
Share Based Compensation of Revenue
3.79% 3.81% 3.69% 3.74%
Interest Coverage
29.41 26.79 25.87 41.53
Operating CF/Net income
1.98 1.94 2.06 1.03
Depreciation/Fixed assets
1.45 1.31 1.12 1.17
Capex/Depreciation
(0.10) (0.09) (0.08) 1.54
Revenue per Share
14.19 12.77 11.65 10.60
Operating CF per Share
6.98 5.73 5.44 5.21
Capex per Share
(0.11) (0.08) (0.06) 1.10
Capex to Sales
0.01 0.01 0.01 (0.10)

Fold the line items

Columns are period end dates